TORONTO—The federal government’s plan to increasingly regulate the costs of pharmaceuticals could mean Canadians with cystic fibrosis and other rare diseases may soon lose access to new innovative drug treatments, finds a new study released today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank.
Starting next year, the Patented Medicine Prices Review Board (PMPRB)—a federal body that regulates the prices of all patented medicines in Canada—is planning to use new rules for establishing drug prices with the goal of lowering costs.